Metastatic Breast Cancer in 28 Years Old Man

Česká verzia

Authors: M. Drahokoupilová
Authors place of work: FNsP Milosrdní bratia, s. r. o, Bratislava, Slovenská republika
Published in the journal: Klin Onkol 2010; 23(4): 264-268
Category: Kazuistiky

Summary

Backgrounds:
Male breast cancer only makes up about 1% of all malignancies in the male population; the median age at time of diagnosis is 68 years. The treatment procedures used in clinical practice are those confirmed by studies on women.

Case:
Presented is a case of a 28‑year- old man with breast cancer in the fourth clinical stage.

Results:
The patient was treated with the addition of trastuzumab to chemotherapy, radiotherapy, hormone treatment, with disease progression with lapatinib added to chemotherapy. 18 months after initiation of therapy, the patient died.

Conclusion:
Despite the increase in incidence, male breast cancer remains a rare diagnosis and treatment data are not confirmed in prospective randomized studies.

Key words:
breast cancer – male – treatment

Zdroje

1. Romics L, O’Brien ME, Relihan N et al. Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. J Med Case Reports 2009; 3: 13.

2. Dimitrov N, Nagpal S, Chitneny S. Management of male breast cancer. Oncol Rev 2008; 2: 44– 52.

3. Ewertz M, Holmberg L, Karjalainen S et al. Incidence of male breast cancer in Scandinavia, 1943– 1982. Int J Cancer 1989; 43(1): 27– 31.

4. Luini A, Gatti G, Brenelli F et al. Male breast cancer in a young patient treated with nipple‑ sparing mastectomy. Tumori 2007; 93(1): 118– 120.

5. Giordano SH, Buzdar AU, Hortobagyi GN. Breast Cancer in Men. Ann Intern Med 2002; 137(8): 678– 687.

6. DeVita, Hellman, and Rosenberg‘s Cancer: Principles & Practice of Oncology, Eighth Edition 1617.

7. Crichlow RW. Carcinoma of the male breast. Surg Gynecol Obstet 1972; 134(6): 1011– 1019.

8. Giordano SH. A review of a diagnosis and management of male breast cancer. The Oncologist 2005; 10(7): 471– 479.

9. Rudlowski C, Friedrichs N, Faridi A et al. Her‑ 2neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84(3): 215– 223.

10. Kwiatkowska E, Teresiak M, Filas V et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 2003; 9(12): 4452– 4459.

11. Lanitis S, Rice AJ, Vaughan A et al. Diagnosis and Management of Male Breast Cancer. World J Surg 2008; 32(11): 2471– 2476.

12. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007; 9(3):192– 194.

13. Johnston S, Pippen J, Pivot X et al. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First‑ Line Therapy for Postmenopausal Hormone Receptor‑ Positive Metastatic Breast Cancer. J Clin Oncol 2009; 27(33): 5538– 5546.